T6199

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50:10/39 nM).

HTT-D3 is an orally active, highly efficient Huntington splicing modulator. It induces HTT mRNA degradation, reduces HTT protein levels, and inhibits P-glycoprotein (P-gp) efflux. This compound can be used in Huntington's disease research.

Topoisomerase I/II inhibitor 3 (compound 7) is a potent dual inhibitor of topoisomerase I (Topo I) and II (Topo II) that inhibits the PI3K/Akt/mTOR signaling pathway, subsequently inhibiting cell proliferation, invasion, and migration, and inducing apoptosis. This compound has research value in liver cancer.

SIK1 activator 1 can enhances the SIK1 phosphorylation and ameliorated the hyperglyceamia of type 2 diabetic mice. SIK1 activator 1 exhibited remarkable inhibitory activity on hepatic gluconeogenesis.

AChE/BChE-IN-8 (Compound 5a) is an uncompetitive AChE and mixed BChE inhibitor with Ki values of 0.788 μM against Electrophorus electricus AChE (EeAChE) and 2.364 μM against equine BChE (eqBChE), respectively. AChE/BChE-IN-8 demonstrates blood-brain barrier permeability and low cytotoxicity.

Y-29794 (Compound 2) is a potent, covalent inhibitor of prolyl oligopeptidase (POP) with a Ki of 0.95 nM, holding research value in neurodegenerative diseases and cancer.

Antiproliferative agent-6 (compound 8a) is a potent antitumor compound exhibiting antiproliferative activity. It inhibits cancer cell lines HCT116, MCF-7, H460, and non-tumor aneuploid immortal keratinocyte HaCaT cells with GI50 values of 0.5 μM, 2 μM, 0.7 μM, and 3.5 μM, respectively.

UGM-IN-3 (compound 10a) is an inhibitor of UDP-galactopyranose mutase (UGM) with a Kd of 66 μM and inhibits the growth of Mycobacterium tuberculosis (MIC= 6.2 μg/mL).

Quinidine is a potent, orally active, selective inhibitor of cytochrome P450db. Quinidine hydrobromide is a K + channel blocker (IC 50= 19.9 μM). Quinidine hydrobromide shows antiarrhythmic activity. Quinidine hydrobromide can be used for malaria research.